Levodopa and dopamine agonist phobia in Parkinson’s Disease — does it really matter? A survey on treatment patterns in Polish tertiary centres
, 123, 1, 4, 12, 1, 12, 5, 6, 12
Abstract
Aim of study. To investigate the treatment strategies of Parkinson’s Disease (PD) among movement disorder specialists in tertiary centres in Poland, and how literature warnings (levodopa and dopamine agonist phobia) have influenced their practice.
Material and methods. The survey was conducted between 30 November, 2020 and 18 October, 2021, in four Polish tertiary referral centres for PD (two in Gdansk, one in Sosnowiec, and one in Warsaw). Movement disorder specialists collected information on the treatment of 494 consecutive patients diagnosed with PD. The questionnaire included information on the age of the patient, the duration of PD, the Hoehn&Yahr (H&Y) stage, comorbidities, pharmacotherapy, and advanced PD therapies i.e. deep brain stimulation (DBS), levodopa/carbidopa intestinal gel (LCIG), and continuous subcutaneous apomorphine infusions (CSAI).
Results. Levodopa was the most prescribed medication (n = 465/494), followed by dopamine agonists (n = 292/494). The mean dose of levodopa was 810.58 ± 473.11 mg, and it did not exceed 2,000 mg/d in 98.5% of patients. The mean doses of dopamine agonists used were relatively low (ropinirole 8.64 ± 3.94 mg, pramipexole base 1.76 ± 0.65mg). Amantadine (n = 197/494) and MAO-B inhibitors (n = 202/494) were prescribed less frequently. Catechol-o-methyltransferase (COMT) inhibitors (n = 7/494) and anticholinergics (n = 4/494) were rarely used in the studied population. Complex polytherapy with three or more PD medications was the most often used treatment strategy (n = 223/494).
Conclusions and clinical implications. Levodopa remains the gold standard in PD treatment in tertiary movement disorder centres in Poland. Dopamine agonists formed the second most frequently prescribed group of medications; however, the observed low dosages of both levodopa and dopamine agonists may suggest a cautious approach by clinicians. Amantadine and MAO-B inhibitors (mainly rasagiline) constituted important elements of PD pharmacotherapy. The high prevalence of complex polytherapy underlines the complexity of PD management, the cautious use of single medication at high doses, and the need for personalised therapeutic strategies.
Keywords: Parkinson’s Diseaselevodopa phobiadopamine agonist phobiaprescription patterns
References
- Siuda J. Importance of non-motor symptoms in PD and atypical parkinsonism. Neurol Neurochir Pol. 2021; 55(6): 503–507.
- Golbe LI, Leyton CE. Life expectancy in Parkinson disease. Neurology. 2018; 91(22): 991–992.
- Titova N, Levin O, Katunina E, et al. 'Levodopa Phobia': a review of a not uncommon and consequential phenomenon. NPJ Parkinsons Dis. 2018; 4: 31.
- Rota S, Boura I, Batzu L, et al. 'Dopamine agonist Phobia' in Parkinson's disease: when does it matter? Implications for non-motor symptoms and personalized medicine. Expert Rev Neurother. 2020; 20(9): 953–965.
- Fahn S. The history of dopamine and levodopa in the treatment of Parkinson's disease. Mov Disord. 2008; 23 Suppl 3: S497–S508.
- Kakkar AK, Dahiya N. Management of Parkinson׳s disease: Current and future pharmacotherapy. Eur J Pharmacol. 2015; 750: 74–81.
- Marconi S, Zwingers T. Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease. Eur Rev Med Pharmacol Sci. 2014; 18(13): 1879–1882.
- Cereda E, Cilia R, Canesi M, et al. Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study. J Neurol. 2017; 264(6): 1254–1263.
- Kong M, Ba M, Ren C, et al. An updated meta-analysis of amantadine for treating dyskinesia in Parkinson's disease. Oncotarget. 2017; 8(34): 57316–57326.
- Perez-Lloret S, Rascol O. Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia. J Neural Transm (Vienna). 2018; 125(8): 1237–1250.
- Brocks DR. Anticholinergic drugs used in Parkinson's disease: An overlooked class of drugs from a pharmacokinetic perspective. J Pharm Pharm Sci. 1999; 2(2): 39–46.
- Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988; 51(6): 745–752.
- Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015; 30(12): 1591–1601.
- Przytuła F, Kasprzak J, Dulski J, et al. Morbidity and severity of COVID-19 in patients with Parkinson's disease treated with amantadine - A multicenter, retrospective, observational study. Parkinsonism Relat Disord. 2023; 106: 105238.
- Vilas D, Pont-Sunyer C, Tolosa E. Impulse control disorders in Parkinson's disease. Parkinsonism Relat Disord. 2012; 18 Suppl 1: S80–S84.
- Weintraub D, Nirenberg MJ. Impulse control and related disorders in Parkinson's disease. Neurodegener Dis. 2013; 11(2): 63–71.
- Seki M, Kawata Y, Hayashi A, et al. Prescribing patterns and determinants for elderly patients with Parkinson's disease in Japan: a retrospective observational study using insurance claims databases. Front Neurol. 2023; 14: 1162016.
- Takeda A, Baba T, Watanabe J, et al. Levodopa Prescription Patterns in Patients with Advanced Parkinson's Disease: A Japanese Database Analysis. Parkinsons Dis. 2023; 2023: 9404207.
- Chaudhuri KR, Kovács N, Pontieri FE, et al. Levodopa Carbidopa Intestinal Gel in Advanced Parkinson's Disease: DUOGLOBE Final 3-Year Results. J Parkinsons Dis. 2023; 13(5): 769–783.
- Surathi P, Kamble N, Bhalsing KS, et al. Prescribing Pattern for Parkinson's Disease in Indian Community before Referral to Tertiary Center. Can J Neurol Sci. 2017; 44(6): 705–710.
- Dahodwala N, Willis AW, Li P, et al. Prevalence and Correlates of Anti-Parkinson Drug Use in a Nationally Representative Sample. Mov Disord Clin Pract. 2017; 4(3): 335–341.
- Rodriguez-Sanchez F, Rodriguez-Blazquez C, Bielza C, et al. Identifying Parkinson's disease subtypes with motor and non-motor symptoms via model-based multi-partition clustering. Sci Rep. 2021; 11(1): 23645.
- Suh DC, Pahwa R, Mallya U. Treatment patterns and associated costs with Parkinson's disease levodopa induced dyskinesia. J Neurol Sci. 2012; 319(1-2): 24–31.
- Sitek EJ, Sołtan W, Wieczorek D, et al. Self-awareness of memory function in Parkinson's disease in relation to mood and symptom severity. Aging Ment Health. 2011; 15(2): 150–156.
- Swinn L, Schrag A, Viswanathan R, et al. Sweating dysfunction in Parkinson's disease. Mov Disord. 2003; 18(12): 1459–1463.
- Zach M, Friedman A, Sławek J, et al. Quality of life in Polish patients with long-lasting Parkinson's disease. Mov Disord. 2004; 19(6): 667–672.
- Navaratnam P, Arcona S, Friedman HS, et al. Natural history and patterns of treatment change in Parkinson's disease: A retrospective chart review. Clin Park Relat Disord. 2022; 6: 100125.
- Zhao H, Ning Yi, Cooper J, et al. Indirect Comparison of Ropinirole and Pramipexole as Levodopa Adjunctive Therapy in Advanced Parkinson's Disease: A Systematic Review and Network Meta-Analysis. Adv Ther. 2019; 36(6): 1252–1265.
- Pahwa R, Stacy MA, Factor SA, et al. EASE-PD Adjunct Study Investigators. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology. 2007; 68(14): 1108–1115.
- Zesiewicz TA, Chriscoe S, Jimenez T, et al. A randomized, fixed-dose, dose-response study of ropinirole prolonged release in advanced Parkinson's disease. Neurodegener Dis Manag. 2017; 7(1): 61–72.
- Wang Y, Sun SG, Zhu SQ, et al. Analysis of pramipexole dose-response relationships in Parkinson's disease. Drug Des Devel Ther. 2017; 11: 83–89.
- Perez-Lloret S, Rey MV, Ratti L, et al. Pramipexole for the treatment of early Parkinson's disease. Expert Rev Neurother. 2011; 11(7): 925–935.
- Perez-Lloret S, Rascol O. Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease. CNS Drugs. 2016; 30(8): 703–717.
- Hauser RA, Slawek J, Barone P, et al. Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson's disease. BMC Neurol. 2016; 16: 90.
- Jost WH. A critical appraisal of MAO-B inhibitors in the treatment of Parkinson's disease. J Neural Transm (Vienna). 2022; 129(5-6): 723–736.
- Rascol O, Fabbri M, Poewe W. Amantadine in the treatment of Parkinson's disease and other movement disorders. Lancet Neurol. 2021; 20(12): 1048–1056.
- Kim A, Kim YE, Yun JiY, et al. Amantadine and the Risk of Dyskinesia in Patients with Early Parkinson's Disease: An Open-Label, Pragmatic Trial. J Mov Disord. 2018; 11(2): 65–71.
- Olanow CW, Schapira AH. The place of COMT inhibitors in the armamentarium of drugs for the treatment of Parkinson's disease. Neurology. 2000; 55(11_suppl_4): 69–71.
- Larsen JP, Worm-Petersen J, Sidén A, et al. NOMESAFE Study Group. The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease. Eur J Neurol. 2003; 10(2): 137–146.
- Ehrt U, Broich K, Larsen JP, et al. Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study. J Neurol Neurosurg Psychiatry. 2010; 81(2): 160–165.
- Malkiewicz JJ, Kasprzyk AG, Waksmundzki D, et al. Risk factors for dementia in Parkinson's Disease - the overuse of anticholinergic drugs. Neurol Neurochir Pol. 2023; 57(5): 405–413.
- Suzuki M, Arai M, Hayashi A, et al. Prescription pattern of anti-Parkinson's disease drugs in Japan based on a nationwide medical claims database. eNeurologicalSci. 2020; 20: 100257.
- Liu XQ, Wang XY, Shen HM, et al. Real-World Prescription Patterns For Patients With Young-Onset Parkinson's Disease in China: A Trend Analysis From 2014 to 2019. Front Pharmacol. 2022; 13: 858139.
